1910 related articles for article (PubMed ID: 28978710)
41. Broadly Protective CD8
Zhang H; Zheng H; Guo P; Hu L; Wang Z; Wang J; Ju Y; Meng S
J Virol; 2021 May; 95(12):. PubMed ID: 33827939
[TBL] [Abstract][Full Text] [Related]
42. Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure.
Wei CJ; Yassine HM; McTamney PM; Gall JG; Whittle JR; Boyington JC; Nabel GJ
Sci Transl Med; 2012 Aug; 4(147):147ra114. PubMed ID: 22896678
[TBL] [Abstract][Full Text] [Related]
43. A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets.
Ross TM; Mahmood K; Crevar CJ; Schneider-Ohrum K; Heaton PM; Bright RA
PLoS One; 2009 Jun; 4(6):e6032. PubMed ID: 19554101
[TBL] [Abstract][Full Text] [Related]
44. A computationally optimized broadly reactive hemagglutinin vaccine elicits neutralizing antibodies against influenza B viruses from both lineages.
Carlock MA; Ross TM
Sci Rep; 2023 Sep; 13(1):15911. PubMed ID: 37741893
[TBL] [Abstract][Full Text] [Related]
45. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
[TBL] [Abstract][Full Text] [Related]
46. The antigenic landscape of human influenza N2 neuraminidases from 2009 until 2017.
Catani JPP; Smet A; Ysenbaert T; Vuylsteke M; Bottu G; Mathys J; Botzki A; Cortes-Garcia G; Strugnell T; Gomila R; Hamberger J; Catalan J; Ustyugova IV; Farrell T; Stegalkina S; Ray S; LaRue L; Saelens X; Vogel TU
Elife; 2024 May; 12():. PubMed ID: 38805550
[TBL] [Abstract][Full Text] [Related]
47. Broad cross-protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine.
Yan J; Morrow MP; Chu JS; Racine T; Reed CC; Khan AS; Broderick KE; Kim JJ; Kobinger GP; Sardesai NY; Weiner DB
Vaccine; 2018 May; 36(22):3079-3089. PubMed ID: 29100705
[TBL] [Abstract][Full Text] [Related]
48. Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets.
Liu YV; Massare MJ; Pearce MB; Sun X; Belser JA; Maines TR; Creager HM; Glenn GM; Pushko P; Smith GE; Tumpey TM
Vaccine; 2015 Apr; 33(18):2152-8. PubMed ID: 25772674
[TBL] [Abstract][Full Text] [Related]
49. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections.
Liu G; Song L; Reiserova L; Trivedi U; Li H; Liu X; Noah D; Hou F; Weaver B; Tussey L
Vaccine; 2012 Nov; 30(48):6833-8. PubMed ID: 23000130
[TBL] [Abstract][Full Text] [Related]
50. Multi-Influenza HA Subtype Protection of Ferrets Vaccinated with an N1 COBRA-Based Neuraminidase.
Skarlupka AL; Zhang X; Blas-Machado U; Sumner SF; Ross TM
Viruses; 2023 Jan; 15(1):. PubMed ID: 36680224
[TBL] [Abstract][Full Text] [Related]
51. Infection of Ferrets with Influenza Virus Elicits a Light Chain-Biased Antibody Response against Hemagglutinin.
Kirchenbaum GA; Allen JD; Layman TS; Sautto GA; Ross TM
J Immunol; 2017 Dec; 199(11):3798-3807. PubMed ID: 29079697
[TBL] [Abstract][Full Text] [Related]
52. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
[TBL] [Abstract][Full Text] [Related]
53. Pandemic influenza 1918 H1N1 and 1968 H3N2 DNA vaccines induce cross-reactive immunity in ferrets against infection with viruses drifted for decades.
Bragstad K; Martel CJ; Thomsen JS; Jensen KL; Nielsen LP; Aasted B; Fomsgaard A
Influenza Other Respir Viruses; 2011 Jan; 5(1):13-23. PubMed ID: 21138536
[TBL] [Abstract][Full Text] [Related]
54. Characterization of Humoral Responses Induced by an H7N9 Influenza Virus-Like Particle Vaccine in BALB/C Mice.
Zhang L; Lu J; Chen Y; Shi F; Yu H; Huang C; Cui L; Shi Z; Jiao Y; Hu Y
Viruses; 2015 Aug; 7(8):4369-84. PubMed ID: 26248076
[TBL] [Abstract][Full Text] [Related]
55. Vaccine Efficacy Induced by 2009 Pandemic H1N1 Virus-Like Particles Differs from that Induced by Split Influenza Virus.
Lee GJ; Chu KB; Inn KS; Moon EK; Quan FS
Immunol Invest; 2020 Oct; 49(7):781-793. PubMed ID: 31774021
[TBL] [Abstract][Full Text] [Related]
56. Vaccination with 2014-15 Seasonal Inactivated Influenza Vaccine Elicits Cross-Reactive Anti-HA Antibodies with Strong ADCC Against Antigenically Drifted Circulating H3N2 Virus in Humans.
Zhong W; Gross FL; Holiday C; Jefferson SN; Bai Y; Liu F; Katz JM; Levine MZ
Viral Immunol; 2016 May; 29(4):259-62. PubMed ID: 26950058
[TBL] [Abstract][Full Text] [Related]
57. Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses.
Kamlangdee A; Kingstad-Bakke B; Osorio JE
J Virol; 2016 Aug; 90(15):6771-6783. PubMed ID: 27194759
[TBL] [Abstract][Full Text] [Related]
58. Sequential Infection in Ferrets with Antigenically Distinct Seasonal H1N1 Influenza Viruses Boosts Hemagglutinin Stalk-Specific Antibodies.
Kirchenbaum GA; Carter DM; Ross TM
J Virol; 2016 Jan; 90(2):1116-28. PubMed ID: 26559834
[TBL] [Abstract][Full Text] [Related]
59. H3N2 influenza viruses in humans: Viral mechanisms, evolution, and evaluation.
Allen JD; Ross TM
Hum Vaccin Immunother; 2018; 14(8):1840-1847. PubMed ID: 29641358
[TBL] [Abstract][Full Text] [Related]
60. Conserved stem fragment from H3 influenza hemagglutinin elicits cross-clade neutralizing antibodies through stalk-targeted blocking of conformational change during membrane fusion.
Gong X; Yin H; Shi Y; Guan S; He X; Yang L; Yu Y; Kuai Z; Jiang C; Kong W; Wang S; Shan Y
Immunol Lett; 2016 Apr; 172():11-20. PubMed ID: 26875772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
